Last checked at 16 May 2024 10:27
AstraZeneca trials yield positive results for immunocompromised patients
(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades7,522
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,100.00
Bid:
12,098.00
Ask:
12,100.00
Change:
-66.00 (-0.54%)
Spread:
2.00 (0.017%)
Open:
12,186.00
High:
12,198.00
Low:
12,090.00
Prev. Close:
12,166.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca signs major deal with Grunenthal over Zurampic
Thu, 02nd Jun 2016 07:08
(ShareCast News) - Pharmaceutical and biologics company AstraZeneca announced on Thursday that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America.The FTSE 100 firm received approval from the European Medicines Agency in February for Zurampic, for the adjunctive treatment of hyperuricemia, or excess of uric acid in the blood, in adult patients with uncontrolled gout.Under the terms of the deal, Grünenthal will acquire the exclusive rights to Zurampic in all 28 European Union member states, Switzerland, Iceland, Norway and Lichtenstein, and in all Latin American countries including Mexico, the Dominican Republic and Cuba.Additionally, Grünenthal will obtain the exclusive rights to a fixed-dose combination of lesinurad and allopurinol in those markets - the combination is currently in clinical trials.Grünenthal will submit the fixed-dose combination programme or regulatory review, and will pay AstraZeneca up to $230m in sales and other related milestones over the lifetime of the contract under the terms of the agreement.Grünenthal will also pay tiered, low double-digit royalties on annual product sales, while AstraZeneca will initially manufacture and supply Zurampic to Grünenthal and will undertake the European post-approval commitment on Grünenthal's behalf.From 1 October 2021, Grünenthal has the option to take over manufacturing from AstraZeneca."Grünenthal has an established presence across European and Latin American markets and extensive expertise in inflammatory diseases," said AstraZeneca executive vice president, global product and portfolio strategy Luke Miels."This agreement allows us to further focus our resources on our strategic priorities."Grünenthal CEO Prof Dr Eric-Paul Pâques said the company was highly committed to the research, development and commercialisation of innovative therapies."Zurampic is a strong addition to our existing portfolio of innovative therapies in the areas of inflammatory diseases and chronic pain."We will thus use our capabilities to provide patients in our markets with this innovative new medicine to better control their condition," Prof Dr Pâques explained.
More News
12 May 2024 13:25
Pfizer and AstraZeneca announce new investments of nearly $1 billion in France
PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.
Read more8 May 2024 19:10
Sector movers: Aerospace and Defence, Pharma pace gains
(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.
Read more8 May 2024 17:46
FTSE 100 hits record high, pound slips ahead of BoE verdict
FTSE 100 up 0.5%, FTSE 250 adds 0.4%
*Read more8 May 2024 16:36
London close: Stocks rise further ahead of BoE decision
(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.
Read more8 May 2024 09:44
AstraZeneca says withdraws Covid vaccine "for commercial reasons"
(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.
Read more8 May 2024 09:39
LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more7 May 2024 15:54
Berenberg hikes target price on Astrazeneca
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".
Read more7 May 2024 09:51
LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:
Read more6 May 2024 07:46
AstraZeneca completes collaboration and investment deal with Cellectis
(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.
Read more3 May 2024 12:17
CORRECT: Angle shares up on assay development deal with AstraZeneca
(Correcting company name in headline)
Read more3 May 2024 11:50
Angle shares up on assay development deal with AstraZenaca
(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.
Read more3 May 2024 07:50
LONDON BRIEFING: InterContinental Hotels makes first-quarter progress
(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.
Read more2 May 2024 10:04
AstraZeneca notes positive trial results for Calquence treatment
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.
Read more2 May 2024 07:45
AstraZeneca reports positive results from blood cancer drug trial
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.
Read more